Full text loading...
-
The Evaluation of the Impact of Antibiotic De-escalation among Paediatric Patients Admitted to Tertiary Care Hospital in Ajman, UAE: A Cross-sectional Retrospective Observational Study
- Source: Current Pediatric Reviews, Volume 21, Issue 1, Jan 2025, p. 67 - 74
-
- 22 Oct 2023
- 14 Mar 2024
- 01 Jan 2025
Abstract
Antibiotic de-escalation therapy plays a vital role in reducing the risk of bacterial resistance across the globe. This study elucidates the significance, determinants, and outcomes pertaining to Antibiotic De-escalation (ADE). The ADE is acknowledged as a crucial component within Antimicrobial Stewardship Programs (ASPs). The proliferation of antimicrobial-resistant bacteria arises as an anticipated outcome of the extensive utilization of antibiotics, heightening researchers' apprehensions regarding this global challenge.
The primary objective of the study was to evaluate the usage of antibiotics in terms of clinical outcomes (re-admission within 30 days and therapy outcomes upon discharge), adverse events, duration of de-escalation, and duration of hospitalizations among pediatric patients admitted to a tertiary care hospital due to various infectious diseases.
A retrospective study was conducted during a four-month period, from January 2022 to April 2023, at a tertiary care facility in Ajman, United Arab Emirates. Participants included in this study were based on specific inclusion and exclusion criteria.
A total of 200 pediatric records were screened. The majority of participants, accounting for 66.0%, were female, and 54.0% were classified as Arabs in terms of race. The mean age was 7.5 years (± 2.8). The most prevalent symptoms reported were fever (98%), cough (75%), and sore throat (73%). Male participants were more inclined to present with bacterial infections (88.2%) compared to viral infections (3.8%), bacterial and viral co-illnesses (2.5%), or parasitic infections (1.3%) at the time of admission. Regarding clinical outcomes, 27% of patients were readmitted with the same infection type, while 52% did not experience readmission. The analysis also included information on the number of patients within each antibiotic therapy duration category, alongside the mean duration of antibiotic de-escalation in hours with standard deviation (± SD). The statistical significance of these associations was assessed using P-values, revealing a significant relationship (P < 0.0001) between the duration of antibiotic therapy and the time required for antibiotic de-escalation.
The study's analysis revealed that individuals readmitted to the hospital, irrespective of whether they presented with the same or a different infection type, exhibited prolonged durations of antibiotic de-escalation. This observation underscores the potential influence of the patient's clinical trajectory and the necessity for adjunctive therapeutic interventions on the duration of antibiotic de-escalation.